

# NOVEL APPROACHES FOR PULSATILE DRUG DELIVERY SYSTEM

Syed Gouse Firoz<sup>1</sup>, R. Kothai<sup>2</sup>, B. Arul<sup>3</sup>

<sup>1,2,3</sup>Department of Pharmacology, Vinayaka Missions College of Pharmacy, Vinayaka Missions Research Foundation (Deemed to be University), Salem - 636008, Tamil Nadu, India

Email: kothaiarul@yahoo.co.in

Received: 14 March 2020 Revised and Accepted: 8 July 2020

**ABSTRACT:** With progression of the innovations developed in the arena of pharmaceutical industry, drug delivery system tired a significant development over the past years. These days, the importance of pharmaceutical galanic exploration is revolved towards Chrono pharmaceutical drug delivery system (CDDS). CDDS may convey the medication at the correct spot of activity at the event of time & in the precise quantity based on circadian rhythms, thus providing dimensional and chronological delivery with increasing patient assent. Continued and controlled medication conveyance framework may discharge the medication at a considerably consistent pace of discharge each part of time. Nonetheless, here are numerous cases wherein a steady blood percentage of a medication isn't attractive. In such belongings a pulsatile sedate conveyance can be utilized. In Pulsatile Medication conveyance framework; a heartbeat must be structured so that it can discharge the medication in exceptionally quick way significantly after the long time. The main theme of this current review is to describe the diseases in which CDDS can be implemented, methods that can be used in the existing systems and more focus on time and stimuli induced methods, recent developments in CDDS.

**KEYWORDS:** Pulsatile, lag time, circadian rhythm, time induced, stimuli induced

## I. INTRODUCTION:

The term “Chrono” refers to the reflection in which each metabolic occasion experiences cadenced changes in time. Recent studies reasoned that both sickness states and medication treatment were influenced by a large number of musical deviations that may ensue in the human body<sup>[1]</sup>. Now a days, research on Pulsatile sedate conveyance framework was increases. Pulsatile medicate conveyance framework have a unique mechanism of delivering the drug in a rapid manner even after a long time.”<sup>[2]</sup> However a large portion of the medication conveyance frameworks were intended for steady medication discharge over a delayed timeframe. Pulsatile medicate conveyance framework has a modified medication discharge, with a steady blood levels of a medication which can't generally be attractive [Fig - 1]. Be that as it may, few pulsatile discharge frameworks are accessible because of expected restrictions of the measurements structure size, as well as polymeric materials and their pieces utilized for delivering such dose structures<sup>[3]</sup>. Such a novel medication conveyance has been endeavored for the accompanying maladies recorded in [Table 1]<sup>[4]</sup>.




Fig.: 1.1 Drug Release Profile of Pulsatile Drug Delivery System

Pulsatile devices have many applications as compared with the regions of other medication; where a consistent pace of medication discharge doesn't coordinate the physiological prerequisites of the body. This is the situation after medicines include like hormone created medications. Flow investigates engaged with the field of medication conveyance gadgets, by which activated and additionally pulsatile discharge is accomplished [5].

**Need for chronopharmaceutical drug delivery system [6]**

There are numerous conditions and illnesses where supported discharge details have not showing effective.

Due to the following reasons; changes from customary supported discharge way to deal with present day pulsatile drug delivery system increases

- First pass digestion
- Biological resistance
- Special chronopharmacological requirements
- Local therapeutic need
- Gastric irritation or medicate precariousness in gastric liquid
- Drug retention contrasts in different gastrointestinal sections

**Table 1: Diseases requiring Pulsatile Drug Delivery system**

Disease	Chronological behavior	Drugs used
Arthritis	Pain in the morning and more pain at night	NSAIDs, Glucocorticoids
Asthma	Precipitation of attacks during night or at early morning hour	β2agonist, Antihistaminics
Attention deficit syndrome	Increase in DOPA level in afternoon	Methylphenidate
Cardiovascular diseases	BP is at its lowest during the sleep cycle and raises steeply during the early morning awakening period	Nitroglycerin, Calcium channel blocker, ACE inhibitors etc.
Diabetes mellitus	Increase in the blood sugar level after meal	Sulfonylurea, Insulin, Biguanide
Peptic ulcer	Acid secretion is high in the afternoon and at night	H <sub>2</sub> blocker
Hypercholesterolemia	Cholesterol synthesis is generally higher during night than during day time	HMG CoA reductase inhibitors
Antiretroviral therapy	Protecting the drug from degradation in regions of gastric or upper intestinal mucosa or drugs with extensive first pass metabolism	Acyclovir , Ritonovir

**II. METHODS USED FOR PULSATILE DRUG DELIVERY SYSTEM**

Methods utilized in the pulsatile medicate conveyance framework can be comprehensively arranged into 3 categories;

1. Time measured
2. Incitements persuaded
3. On the exterior controlled

**1. Time controlled pulsatile release system**


In this method, pulsatile discharge is acquired after a particular time period so as to decrease the circadian musicality. Such kind of pulsatile tranquilize conveyance framework contains two parts: one is of prompt discharge type and other one is a beat discharge type.

Different approaches that can be utilized for time controlled pulsatile discharge frameworks are following

- a. Pulsatile system based on Osmosis
- b. Capsule formed framework furnished with discharge controlling attachment
- c. Delivery systems with rupturable covering layer
- d. Delivery system through erodible covering layers

**a. Pulsatile system based on Osmosis <sup>[7]</sup>**


Osmotic structure contains tablet covered through the semipermeable film. Exclusive the case here was an mysterious attachment comprising of osmotically dynamic specialist and the medication content. At the point when the case interacts with the disintegration liquid, the semipermeable layer permitted the passage of water in to the capsule due to presence of small pore, which causes pressure to be developed & the insoluble attachment ousted after a slack time. Such a framework was used to convey methylphenidate utilized in the treatment of consideration shortage hyper movement issue as the pulsatile port system <sup>[8,9]</sup>



**Fig.2 Schematic diagram of osmosis system**

**b. Capsule shaped system providing through release regulatory plug <sup>[10]</sup>**

Single - unit frameworks are created in case structure. The slack time is controlled as an attachment, which gets drove missing by growing or disintegration, & the medication is discharged as a heartbeat from the insoluble container structure the case body. This dose structure comprises of an mysterious container body comprising a medication and swellable & degradable fittings through of elements, for example, hydrophilic polymers or lipids. The slack time can be constrained by controlling the measurement and the situation of the attachment.




**Fig:3 Schematic drawing of release of drug from tablet**

**c. Delivery systems through rupturable covering layer <sup>[11]</sup>**

This system mainly subject to the breaking down of the covering for the arrival of medication. The weight fundamental for the break of the covering can be accomplished by the expanding, disintegrants, bubbly and so on. The slack time can be influenced by water saturation and mechanical opposition of the film.

Eg: BuflomediHcl is used for treatment of peripheral.




**Fig:4-Schematic diagram of drug delivery through rupturable covering layer**

**d. Delivery system through erodible covering coatings <sup>[12]</sup>**

In this system, the center covering drug is covered through the solvent or erodible polymer as external covering and the medication discharge is constrained by the disintegration or disintegration of the external coat.

Time subordinate arrival of the medication can be gotten by upgrading the thickness of the external covering as appeared in fig 5.

Ex: The time clock system & the chronotropic system.



**Fig:5 Schematic diagram of drug delivery through erodible covering layer**

**2. Stimuli brought pulsatile release system <sup>[13]</sup>**

In this method, arrival of the medication after incitement by any organic factor like high temperature, P<sup>H</sup> or any additional chemical agents <sup>[14]</sup>. This method further categorized as six types

- a. Temperature tempted systems
- b. Thermo receptive hydrogel and polymer systems
- c. Chemical stimuli induced pulsatile system
- d. Inflammation - induced pulsatile statement
- e. Drug release from intelligent gels retorting to antibody absorption
- f. pH sensitive drug delivery system

**a. Temperature induced systems:**

Temperature instigated frameworks uses different polymer properties, for example, thermally reversible curl/globule progress of polymer particles growing difference in systems, glass change and translucent liquefying <sup>[15]</sup>.

**b. Thermo receptive hydrogel & polymer systems**

In this system the polymer experiences growing or de - swelling stage in light of the high temperature which tweak tranquilize discharge in distended state<sup>[16,17]</sup>.

**c. Chemical improvements instigated pulsatile system<sup>[18]</sup>**

In a glucose-rich atmosphere, such as the blood level later a meal, the oxidation will stay occurred which changes glucose to gluconic acid by glucose oxidase acts as a catalyst and reduces the pH to 5.8. . This pH alteration incorporates growing of the polymer which brings about insulin discharge. Insulin by excellence of its activity lessens blood glucose smooth & which thus gluconic corrosive equal likewise diminishes & framework goes to the deswelling method subsequently diminishing the insulin discharge.

**d. Inflammation - encouraged pulsatile relief**

During irritation, hydroxyl free radicals are delivered from the phones. The Corruption of hydroxyl free radicals happens due to infusing of hyaluronic corrosive gel at the incendiary locales. Along these lines, it is conceivable to pleasure patients through incendiary infections like rheumatoid joint pain; utilizing calming drug fused Hyaluronic Corrosive gels as implantable drug delivery systems<sup>[19]</sup>.

**e. Drug release after insightful salves reacting to antibody absorption**

There are immense number of bioactive mixes exists in the body. Presently a days, unique gels stayed created which reacted to the adjustment in convergence of bioactive mixes to modify their growing/deswelling qualities. Extraordinary consideration was assumed to antigen-immunizer compound development as the cross-connecting units in the gel, since such collaboration is unmistakable<sup>[20]</sup>. Using the distinction in affiliation consistent's between polymerised antibodies and normally determined antibodies towards explicit antigens, revocable gel growing/deswelling and sedate pervasion deviations happens<sup>[21]</sup>.

**f. pH sensitive drug delivery system**

In this framework, it contains two segments. The first is quick discharge type and the other one is beat discharge type which discharges the medication because of progress in pH<sup>[22]</sup>.

**4. On the exterior controlled systems**

In this method, drug relief is planned by peripheral incentives similar magnetism, ultrasound, electrical influence & irradiation in order to release the drug in a pulsatile method<sup>[23]</sup>.

**Advantages of chronopharmaceutical drug delivery system<sup>[24]</sup>**

- Predictable, reproducible and short gastric residence time.
- Bio availability is increased.
- Reduction in side effects and dosage frequency
- Increases absorption & bioavailability as related with the conventional instantaneous release or sustained released drugs.
- Low cost to patients as the fewer dosage is enough
- Drug adjusts to suit heart rhythms to body capacity or infection.

**Limitations of chronopharmaceutical drug delivery system<sup>[25]</sup>**

- Lack of manufacturing units
- Complicated Technologies were adopted so highly skilled man power required
- Multiple manufacturing steps and large number of process variables.
- Homogeneity covered barrier is compulsory to assure the predictability of delay time.
- Cost of production is higher as it involves advanced technology
- Instantaneous extraction of drug is not conceivable.

Some of the marketed drugs based on pulsatile drug delivery technologies was shown in the following table.no.2

**Table No.2 List of the marketed pulsatile drug delivery technologies used:**

S.No	Registered trademark	Drug	Technology	Indications	References
1	Sanctura XR	Trospium chloride	Pellet coating technology	Overactive bladder (OAB) symptom	Chancellor M <i>et al</i> <sup>[26]</sup>
2	Invega	Paliperidone	OROS technology	Schizophrenia	Pani L <i>et al</i> <sup>[27]</sup>
3	Cardizem LA	Diltiazem HCl	CEFORM microsphere technology	Hypertension	Ezeugo,U <i>et al</i> <sup>[28]</sup>
4	Seroquel XR	Quetiapine Fumarate	Hydrophilic matrix technology	Depressive Disorder	Weisler R <i>et al</i> <sup>[29]</sup>
5	Glumetza	Metformin HCl	AcuForm technology	Type II diabetes	Schwartz SL <i>et al</i> <sup>[30]</sup>
6	Cystrin CR	Oxybutynin HCl	TIMERx technology	Urinary incontinence	Julian F G <i>et al</i> <sup>[31]</sup>
7	Ritalin LA	Methylphenidate HCl	SODAS technology B	Attention deficit hyperactivity disorder	Biederman J <i>et al</i> <sup>[32]</sup>
8	Coruno	Molsidomine	Geomatrix technology	Chronic angina pectoris	André H <i>et al</i> <sup>[33]</sup>
9	Covera-HS	Verapamil HCl	OROS technology	Hypertension	Smith DH <i>et al</i> <sup>[34]</sup>

### III. CONCLUSION:

It tends to be inferred that there is a need of new medication conveyance frameworks that can builds restorative advantages to the patients. Chronopharmaceutical medicate conveyance framework offers an answer for conveyance of medications displaying chronopharmacological conduct, broad first pass digestion, need of evening time dosing at ideal time, ideal spot and in right amount. These frameworks can successfully treat illnesses with non-consistent medication treatments, for example, diabetes, asthma, joint pain and so on. These contemplations ought to guarantee that the current elevated level of enthusiasm for this zone would extend well in to future and guarantee in the improvement of personal satisfaction.

### IV. REFERENCES

- [1]. Chourasia MK, Jain SK. Chronopharmaceutics, Pulsatile drug delivery system as current trend. J. Pharm. Pharm. Sci, 2003;6:33-66.
- [2]. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics, Adv. Drug Del. Reviews 2007;59:828-851.
- [3]. Rajkumar K, SainathGoud R, SuryasriLavanya A, Sangamesh T, Pandey D. Current techniques in pulsatile drug delivery: A review. Int Res J Pharm 2013;4(3):77-84

- [4]. Gohel M C, Sumitra M. G. Modulation of active pharmaceutical material release from a novel 'tablet in capsule system' containing an effervescent blend. *J.Control. Release*, 2002, 79: 157–164.
- [5]. Patel JD, Aneja K, Majumdar SH. Pulsatile Drug Delivery System: An User Friendly Dosage Form. *J.Control. Release*, 2010;2(2):204-215.
- [6]. Krogel I, Bodmeier R. Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. *Pharm Res* 1999;16(9):1424-1429
- [7]. Krogel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by erodible plug. *Pharm Res*, 1998;15:474-81
- [8]. Cai K, Luo Z, Hu Y. magnetically triggered reversible controlled drug delivery from micro fabricated polymeric multi reservoir devices. *Adv. Mater*, 2009;21:4045–4049
- [9]. Kulkarni RV, Biswanath SA. Electroresponsive polyacrylamide-grafted-xanthan hydrogels for drug delivery. *J. Bioactive Compatible Poly* 2009;24:368- 384.
- [10]. Rajkumarkotha et al –Current techniques in pulsatile drug delivery *Reviews* 2013;4(3):77–84
- [11]. Dey NS, Majumdar S, Rao MEB. Multiparticulate drug delivery systems for controlled release. *Tropi. J. Pharm. Res*, 2008;7(3):1067-1075.
- [12]. Jessy S, Vishal P. Novel Floating Pulsatile Approach for Chronotherapeutic Release of Indomethacin. *Dhaka Univ. J. Pharm. Sci* 2007;6(1):37-41.
- [13]. Youan BC, Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery, *J.Control. Rel*, 2004; 98: 337–353.
- [14]. AnilKumar S N, Kavitha K, Vinaykumar K. Development of chronopharmaceutical drug delivery system of trimetazidine hydrochloride for angina pectoris. *Int.J.Drug Dev. & Res*, 2010;2(2): 371-378.
- [15]. Najmuddin M, Vishal Ashok Patel, Azgar Ali, Shelar S, Tousif K. Development and evaluation of pulsatile drug delivery system of flurbiprofen. *Res J of Pharm Bio and Che Sci*.2010; 1(2): 285- 90.
- [16]. Mastiholimath VS, Dandagi PM, Jain SS, Gadad AP, Kulkarni AR. Time and pH dependent colon specific colon specific, pulsatile delivery of theophylline for nocturnal asthma. *Int J pharm* 2006;328:49-56.
- [17]. Gohel MC, Manhapra SG. Modulation of active pharmaceutical material release from a novel 'tablet in capsule system' containing an effervescent blend. *J ContRel*. 2002;79:157-164.
- [18]. Sandeep Singh, Marina Koland. Formulation and evaluation of pulsatile drug delivery systems of glipizide for the management of type-ii diabetes mellitus. *Journal of Drug Delivery & Therapeutics*. 2016; 6(1):11-18.
- [19]. Gandhi BR, Mundada AS and Gandhi PP: Chronopharmaceutics: as a clinically relevant drug delivery system. *Drug delivery* 2011; 18(1); 1-18.
- [20]. Kumar Amit and Ranga Sonam :Pulsatile Drug Delivery System :Method and Technology Review *Int.J.Drug Dev& Res.*, 2012(4)4:95-107.
- [21]. Janugade B.U.,PatilS.V.,Lade P.D. Formulation and evaluation of press coated monteluast sod. Tablets for pulsatile drug delivery system. *Int J Chem Tech Res*, 2009;1:690-691
- [22]. Qureshi J., Mohd A., Ahuja A., Baboota S, Ali J. Chronomodulated drug delivery system of salbutamol sulphate for treatment of nocturnal Asthma. *Indian J Pharm Sci*, 2008; 70 (3): 351-356
- [23]. Cutolo M., Straub R.H. Circadian rhythms in arthritis: Hormonal effects on the immune / inflammatory reaction. *Autoimmun Rev*, 2008; 7: 223-228
- [24]. Roy P., Shahiwala A. Statistical optimization of ranitidine HCl floating pulsatile delivery system for chronotherapy of nocturnal acid breakthrough. *Eur J Pharm Sci*, 2009; 37: 363-369.
- [25]. Levi F, Christian F, Abdoulaye K, De la Valette L, Focan- Henrard D, Baron B, Kreutz F, Giacchetti S. Implication of circadian clocks for the rhythmic delivery of cancer therapeutics. *Adv. Drug Delivery Rev* ,2007;59:1015-1035.

- [26]. Chancellor M, Oefelein M, Vasavada S. Obesity is associated with a more severe OAB disease state. Once daily trosipium chloride XR is efficacious in the obese patient with the OAB syndrome. *Neurourol.Urodynam.*2010; 29:551–554.
- [27]. Pani L, Marchese G, Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release, *Expert Opinion on Drug Delivery*, 2009; 6(3): 319–331, 2009.
- [28]. Ezeugo, U. and Glasser, S. P. Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases. *Expert Opin Pharmacother*, 2009; 10: 485-491.
- [29]. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. *CNS Spectr.* 2009; 14(6):299-313.
- [30]. Schwartz SL, Wu JF, Berner B. Metformin extended release for the treatment of type 2 diabetes mellitus. *Expert Opin Pharmacother.* 2006;7(6):803-809.
- [31]. Julian F. Guest, Dele Abegunde, Francis J. Ruiz. Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria. *Clinical Drug Investigation*2004; 24 (6): 305-321.
- [32]. Biederman, J, Quinn, D, Weiss, M et al, Efficacy and safety of Ritalin, LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. *Paediatr Drugs.* 2003; 5:833–841.
- [33]. André Herchuelz., Fabienne Carreer-Bruhwyler, Jacques Crommen. Clinical pharmacokinetics of once-daily molsidomine From immediate-release to prolonged-release once-daily formulations. *American Journal of Drug Delivery* 2004; 2 (2): 131-141
- [34]. Smith DH. Pharmacology of cardiovascular chronotherapeutic agents. *Am* 2001; 14(92):296-301.
- [35]. SOWMYA, C., et al. "DEVELOPMENT AND EVALUATION OF COLON SPECIFIC PULSATILE DRUG DELIVERY OF MONTELUKAST SODIUM FOR NOCTURNAL ASTHMA." *International Journal of Medicine and Pharmaceutical Science (IJMPS)* 9.1 (2019):1-12.
- [36]. BEGAM, M. JANNATH, and M. DEIVANAYAKI. "AN UNSTEADY PULSATILE FLOW OF SOME MHD NON-NEWTONIAN NANOFLUIDS WITH HALL CURRENT AND ION SLIP THROUGH A POROUS MEDIUM." *International Journal of Mechanical and Production Engineering Research and Development (IJMPERD)* 9.4 (2019):111-118.
- [37]. JAYARAMAN, KARTHICK. "NANOMEDICINE: FATE AND FORTUNE IN FUTURE TO TAILOR A DEVICE AT A BILLIONTH OF A METER, ABOUT HALF THE WIDTH OF A DNA." *International Journal of General Medicine and Pharmacy (IJGMP)* 5.3 (2016):19-24.
- [38]. VASUDHA, D., et al. "POLYMERS AND PLASTICIZERS USED IN TRANSDERMAL DRUG DELIVERY: AN OVERVIEW." *IASET: International Journal of Applied Chemistry and Pharmaceutical Sciences (IASET: IJACPS)* 1.1 (2016):1-14.
- [39]. Hamadneh, Bandar, A. L. Hayder, and Malik Haddadin. "NOVEL BITTER MELON (MOMORDICA CHARANTIA L.) AND OLIVE LEAVES (OLEA EUROPAEA L.) PHYTOSOMES: PREPARATION AND ITS EVALUATION FOR ANTI-HYPERGLYCEMIC ACTIVITIES BY ORAL GLUCOSE TOLERANCE TEST (OGTT)." *International Journal of Applied and Natural Sciences (IJANS)* 7.3 (2018):31-40.
- [40]. KADAM, PRIYANKA, et al. "Use Of Heart Rate Variability For The Detection Of The Depth Of Anesthesia." *International Journal of Electronics, Communication & Instrumentation Engineering Research and Development (IJECIERD)* 4.3 (2014):27-32